Myriad Ruling: Some Clarity, Some Uncertainty For Biotech

Law360, New York (June 13, 2013, 6:18 PM EDT) -- On June 13, 2013, the United States Supreme Court issued its long-awaited decision in Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, addressing the controversial question of whether DNA is patent-eligible subject matter under 35 U.S.C. § 101. Drawing a line between two different forms of DNA molecules, the Supreme Court held that isolated DNA is an unpatentable product of nature while cDNA is a non-naturally occurring genetic sequence, and is patentable under the statute. Isolated DNA (or isolated genomic DNA) is DNA taken...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.